Group 1 - The core viewpoint of the article is that Kangzheng Pharmaceutical (00867.HK) has announced a secondary listing on the Singapore Exchange, which aims to enhance its business presence in Southeast Asia and tap into the mature investor market in Singapore [1] - The company emphasizes that Southeast Asia, with a population of nearly 700 million, is experiencing rising pharmaceutical demand due to economic growth, an expanding middle class, aging populations, and an increase in non-communicable diseases [1] - Kangzheng Pharmaceutical has established Singapore as its regional headquarters for Southeast Asia and the Middle East [1] Group 2 - Kangzheng Pharmaceutical was listed in Hong Kong on September 28, 2010, and focuses on specialized fields such as cardiovascular, central nervous system, digestive, and ophthalmology [1] - The company currently has five innovative drugs in the commercialization stage, including "Meitai Tong" for psoriasis and "Laifulan" for methylene blue enteric-coated sustained-release tablets, along with three drugs entering national procurement [1] - As of the latest trading session, Kangzheng Pharmaceutical's stock price was HK$12.94, with a total market capitalization of HK$31.567 billion [2]
康哲药业，以介绍方式在新加坡第二上市